Zymergen Inc. (ZY): Price and Financial Metrics

Zymergen Inc. (ZY): $2.43

0.04 (+1.67%)

POWR Rating

Component Grades








Add ZY to Watchlist
Sign Up

Industry: Chemicals




#83 of 88

in industry

ZY Price/Volume Stats

Current price $2.43 52-week high $12.42
Prev. close $2.39 52-week low $1.10
Day low $2.34 Volume 2,368,400
Day high $2.59 Avg. volume 1,229,575
50-day MA $2.65 Dividend yield N/A
200-day MA $2.77 Market Cap 253.58M

ZY Stock Price Chart Interactive Chart >

Zymergen Inc. (ZY) Company Bio

Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.

ZY Latest News Stream

Event/Time News Detail
Loading, please wait...

ZY Latest Social Stream

Loading social stream, please wait...

View Full ZY Social Stream

Latest ZY News From Around the Web

Below are the latest news stories about ZYMERGEN INC that investors may wish to consider to help them evaluate ZY as an investment opportunity.

Ginkgo Bioworks Lifts Guidance After Mixed Q2 Results; Shares Surge

By Yasin Ebrahim

Yahoo | August 15, 2022

Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future

Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.

Yahoo | August 5, 2022

Is Ginkgo Bioworks Putting Its $1.5 Billion Cash Hoard to Good Use?

The synthetic biology leader's healthy cash balance provides plenty of breathing room, but it won't last forever.

Yahoo | August 2, 2022

Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal

Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl

Yahoo | July 25, 2022

Ginkgo to Acquire Zymergen

Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive a

Yahoo | July 25, 2022

Read More 'ZY' Stories Here

ZY Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2023 N/A
2022 0.00%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!